CA3187609A1 - Immunogenic composition against severe acute respiratory syndrome coronavirus 2 (sars-cov-2) - Google Patents

Abstract

Provided an immunogenic composition against severe acute respiratory syndrome coronavirus (SARS-CoV-2), especially to an immunogenic composition having a recombinant SARS-CoV-2 S protein and adjuvant.

Description

Immunogenic Composition Against Severe Acute Respiratory Syndrome Coronavirus

2 (SARS-CoV-2) CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to and the benefit of U.S.
Provisional Application No.
63/040,696, filed on June 18, 2020 and PCT Application No. PCT/US21/020277, filed on March 01, 2021, the disclosure of which is incorporated by reference in its entirety.
BACKGROUND OF THE INVENTION
1. FIELD OF THE INVENTION
[0002] The present invention relates to an immunogenic composition against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), especially to an immunogenic composition having a recombinant SARS-CoV-2 S protein and adjuvant.
2. DESCRIPTION OF THE PRIOR ART

[0003] In the end of 2019, a novel coronavirus emerged and was identified as a cause of a cluster of respiratory infection cases. The viral pathogen did not match any other known virus and was later officially named "severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)."
The official name of the disease caused by SARS-CoV-2 is coronavirus disease (COVID-19). Common symptoms of COVID-19 include fever, dry cough, fatigue, tiredness, muscle or body aches, sore throat, diarrhea, conjunctivitis, headache, loss of taste or smell, a rash on skin, and shortness of breath. While the majority of cases result in mild symptoms, some progress to acute respiratory distress syndrome (ARDS), precipitated by cytokine storm, multi-organ failure, septic shock, and blood clots. The first confirmed death from the coronavirus infection occurred on January 9, and as of 13 June 2021, 175,306,598 confirmed cases of COVID-19, including 3,792,777 deaths, have been reported to the WHO. The numbers are still growing fast.

[0004] To reduce the risk of SARS-CoV-2 infection without curtailing everyday activities, a COVID-19 vaccine is needed. In particular, a COVID-19 vaccine that is able to rapidly induce an SUBSTITUTE SHEET (RULE 26) immune response against SARS-CoV-2 is urgently needed.
SUMMARY OF THE INVENTION

[0005] In one aspect, the present invention provides an immunogenic composition against a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), comprising an antigenic recombinant protein and an adjuvant selected from the group consisting of an aluminum-containing adjuvant, an unmethylated cytosine-phosphate-guanosine (CpG) motif, and a combination thereof, wherein the antigenic recombinant protein substantially consists of residues 14-1208 of SARS-CoV-2 S protein with proline substitutions at residues 986 and 987 and a "GSAS" substitution at residues 682 - 685 and a C-terminal T4 fibritin trimerization domain.

[0006] In another aspect, the present invention provides a method for eliciting an immune response against a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a subject in need thereof, comprising administering to the subject an effective amount of an immunogenic composition of the present invention.

[0007] In another aspect, the present invention provides a method for protecting a subject in need thereof from infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), comprising administering to the subject an effective amount of the immunogenic composition of the present invention.

[0008] In another aspect, the present invention provides a method for preventing a subject in need thereof from contracting COVID-19 disease, comprising administering to the subject an effective amount of the immunogenic composition of the present invention.

[0009] In another aspect, the present invention provides use of the immunogenic composition of the present invention for eliciting an immune response against a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a subject in need thereof.

[0010] In another aspect, the present invention provides use of the immunogenic composition of the present invention for protecting a subject in need thereof from infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

SUBSTITUTE SHEET (RULE 26)

[0011] In another aspect, the present invention provides use of the immunogenic composition of the present invention for preventing a subject in need thereof from contracting COVID-19 disease.

[0012] These and other aspects will become apparent from the following description of the preferred embodiment taken in conjunction with the following drawings.
BRIEF DESCRIPTION OF THE DRAWINGS

[0013] The accompanying drawings illustrate one or more embodiments of the invention and, together with the written description, serve to explain the principles of the invention. Wherever possible, the same reference numbers are used throughout the drawings to refer to the same or like elements of an embodiment.

[0014] FIG. 1 shows the results from neutralization assays using sera from mice immunized with the SARS-CoV-2 S-2P recombinant protein with or without aluminum phosphate adjuvant.

[0015] FIG. 2 shows the results from neutralization assays using sera from mice immunized with different formulations of the SARS-CoV-2 S-2P recombinant protein.

[0016] FIG. 3 shows induction of neutralizing antibodies by CpG 1018 and aluminum hydroxide-adjuvanted SARS-CoV-2 S-2P at 2 weeks post-second injection. BALB/c mice (N = 6 per group) were immunized with 2 dose levels of Chinese hamster ovary (CHO) cell-expressed SARS-CoV-2 S-2P adjuvanted with CpG 1018, aluminum hydroxide or a combination of both 3 weeks apart and the antisera were harvested at 2 weeks after the second injection. The antisera were subjected to neutralization assay with pseudovirus expressing SARS-CoV-2 spike protein to determine the ID50 (left) and ID90 (right) titers of neutralization antibodies. **p < 0.01, ***p <
0.001.

[0017] FIG. 4 shows total anti-S IgG titers in mice immunized with S-2P with adjuvants. Sera from BALB/c mice in FIG. 3 (N = 6 per group) immunized with 0, 1 or 5 lig of S-2P with CpG
1018, aluminum hydroxide or a combination of both were quantified for the total amount of anti-S IgG in an enzyme linked immunosorbent assay (ELISA). ***p < 0.001.

[0018] FIG. 5 shows neutralization of wild-type SARS-CoV-2 virus by antibodies induced by SARS-CoV-2 S-2P adjuvanted with CpG 1018 and aluminum hydroxide. The antisera were collected as described in FIG. 4 (N = 6 per group) and subjected to a neutralization assay with SUBSTITUTE SHEET (RULE 26) wild-type SARS-CoV-2 to determine neutralization antibody titers. **p < 0.01, ***p < 0.001.

[0019] FIG. 6 shows inhibition of pseudoviruses carrying D614D (wild-type) or (variant) versions of the spike protein by mice immunized with S-2P with CpG
1018 and aluminum hydroxide. The antisera of BALB/c mice immunized with 1 or 5 lag of S-2P with 10 CpG 1018 and 50 lig aluminum hydroxide as in Fig. 5 (N = 5 per group due to assay capacity) were collected. Neutralization assays were performed with pseudoviruses with either D616D or D614G spike proteins.

[0020] FIG. 7 shows IFN-y/IL-4, IFN-y/IL-5, and IFN-y/IL-6 ratios. IFN-y, IL-4, IL-5, and IL-6 values from the cytokine assays (N = 6 per group) were used to calculate ratios. Ratio values greater than 1 indicate Thl bias whereas ratio less than 1 indicate Th2 bias responses. *p < 0.05, <0.01.

[0021] FIGS. 8A-8B show neutralizing antibody titers with pseudovirus assay in hamsters 2 weeks after second immunization. Hamsters (N=10 per group) were immunized twice at 3 weeks apart with vehicle control (PBS), 1 lig (LD) or 5 lig (HD) of S-2P adjuvanted with 150 CpG
1018 and 75 lig aluminum hydroxide, or with adjuvant alone. The antisera were harvested at 2 weeks after the second injection and subjected to neutralization assay with pseudovirus expressing SARS-CoV-2 spike protein to determine the ID90 titers of neutralization antibodies (FIG. 8A) and total anti-S IgG antibody titers with ELISA (FIG. 8B). Results are presented as geometric mean with error bars representing 95% confidence interval and statistical significance calculated with Kruskal-Wallis with corrected Dunn's multiple comparisons test. Dotted lines represent lower and upper limits of detection (40 and 5120 in ID90, 100 and 1,638,400 in IgG
ELISA). ***p <0.001, ****p < 0.0001.

[0022] FIGS. 9A-9B show viral load in hamsters 3 or 6 days post infection (dpi) with SARS-CoV-2. The hamsters were euthanized at 3 or 6 dpi and lung tissue samples were collected for viral load determination by quantitative PCR of viral genome RNA (FIG. 9A), and TCID50 assay for virus titer (FIG. 9B). Results are presented as geometric mean with error bars representing 95% confidence interval and statistical significance calculated with Kruskal-Wallis with corrected Dunn's multiple comparisons test. Dotted lines represent lower and limit of detection (100). *p.<
0.05, **p < 0.01.

[0023] FIG. 10 shows lung pathology scoring in hamsters 3 or 6 days post infection (dpi) with SUBSTITUTE SHEET (RULE 26) SARS-CoV-2. The hamsters were euthanized at 3 or 6 dpi and lung tissue samples were collected for sectioning and staining. The histopathology sections were scored as outlined in the methods and the results tabulated. Results are presented as mean of lung pathology scores with error bars representing standard error and statistical significance calculated with one-way ANOVA with Tukey's multiple comparisons test. ****p < 0.0001.

[0024] FIG. 11 shows summary of solicited adverse events in a Phase I clinical trial.
Participants were asked to record solicited local and systemic adverse events in the participant's diary card for up to 7 days after each vaccination. Solicited adverse events (AEs) were tabulated and graded as mild, moderate, or severe.

[0025] FIGS. 12A-12C shows summary of humoral immune response in the Phase I
clinical trial. Sera of participants vaccinated with 5, 15, or 25 lag of MVC-COV1901 were measured for anti-spike IgG by ELISA (FIG. 12A), and neutralization titers were measured by pseudovirus neutralization assay (FIG. 12B) or live virus neutralization assay (FIG. 12C).
Human convalescent sera (HCS) from 35 recovered COVID-19 patients were analyzed by the same assays for comparison and N1BSC 20/130 standard was used in the live virus neutralization assay as a standard (asterisk in FIG. 12C). Bars indicate geometric mean titers and error bars indicate 95% confidence intervals.

[0026] FIG. 13 shows summary of cellular immune response in the Phase I
clinical trial. Cells were stimulated with a Si peptides pool of peptides and incubated at 37 C for 24-48 hours. Cells stimulated with CD3-2 mAb served as a positive control. IFN-y (left panel) or IL-4 (right panel) were detected using an ELISpot assay. The mean of spot-forming units (SFU) counted in peptide pool stimulation triplicate was calculated and normalized by subtracting the mean of the negative control replicates (control media). Results were expressed as SFU per million PBMC. Bars indicate the mean values and error bars indicate standard deviations.

[0027] FIG. 14 shows neutralization of SARS-CoV-2 pseudovirus bearing wildtype or B.1.351 (Beta) variant spike proteins by antisera of rats vaccinated with adjuvanted S-2P. Rats were immunized three times at 2 weeks apart with the indicated amounts of adjuvanted S-2P. Antisera from five males were pooled into one sample and those of 5 females were pooled into another sample. This resulted in two pooled samples (N=2) for each dose group. The antisera were harvested two weeks after the second immunization (Day 29) or two weeks after the third SUBSTITUTE SHEET (RULE 26) immunization (Day 43), pooled as described above and subjected to neutralization assay with pseudovirus expressing SARS-CoV-2 Wuhan wildtype or B.1.351 variant spike protein to determine the ID50 and ID% titers of neutralizing antibodies. Results are presented as bars representing geometric mean titers with symbols representing value of each sample.

[0028] FIGS. 15A-15F show neutralization of SARS-CoV-2 pseudovirus bearing wildtype or variant spike proteins by antisera of clinical trial subjects vaccinated with different does of MVC-COV1901 vaccine. Serum samples from the phase 1 clinical trial of MVC-subjects were collected 4 weeks after the second immunization (56 days from the first immunization). 1D50 neutralizing titers for low dose (LD; FIG. 15A), mid-dose (MD; FIG. 15B), high dose (HD; FIG. 15C), ID90 neutralizing titers for low dose (LD; FIG.
15D), mid-dose (MD;
FIG. 15E), high dose (HD; FIG. 15F), and all dose groups were measured with pseudovirus neutralization assays. Results are represented with each dot representing individual serum sample neutralizing titer. Kruskal-Wallis with corrected Dunn's multiple comparisons test was performed and statistical significance of variants relative to wildtype is shown above respective column. **p <0.01, ***p < 0.001, ****p < 0.0001.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

[0029] The present invention relates to an immunogenic composition against SARS-CoV-2.
The immunogenic composition comprises an antigenic recombinant protein and an adjuvant containing an aluminum-containing adjuvant and/or an unmethylated cytosine-phosphate-guanosine (CpG) motif The antigenic recombinant protein comprises residues 14-1208 of SARS-CoV-2 S protein with proline substitutions at residues 986 and 987 and a "GSAS" substitution at residues 682 - 685 and a C-terminal T4 fibritin trimerization domain.

[0030] In some embodiments, the residues 14-1208 of SARS-CoV-2 S protein with proline substitutions at residues 986 and 987 and a "GSAS" substitution at residues 682 ¨ 685 comprise an amino acid sequence of SEQ ID NO: 1 or the amino acid sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% to SEQ ID NO: 1.

[0031] In some embodiments, the C-terminal T4 fibritin trimerization motif comprises an amino acid sequence of SEQ ID NO: 2 or the amino acid sequence at least 90%, 91%, 92%, 93%, SUBSTITUTE SHEET (RULE 26) 94%, 95%, 96%, 97%, 98%, or 99% to SEQ ID NO: 2.

[0032] In some embodiments, the antigenic recombinant protein comprises an amino acid sequence of SEQ ID NO: 5 or 6 or the amino acid sequence at least 90%, 95%, 96%, 97%, 98%, or 99% to SEQ ID NO: 5 or 6.

[0033] In some embodiments, the aluminum-containing adjuvant comprises aluminum hydroxide, aluminum oxyhydroxide, aluminum hydroxide gel, aluminum phosphate, aluminum phosphate gel, aluminum hydroxyphosphate, aluminum hydroxyphosphate sulfate, amorphous aluminum hydroxyphosphate sulfate, potassium aluminum sulfate, aluminum monostearate or a combination thereof.

[0034] In some embodiments, a 0.5 ml dose of the immunogenic composition comprises from about 250 to about 500 ps Al3+, or about 375 lag Al3+.

[0035] In some embodiments, the unmethylated CpG motif comprises a synthetic oligodeoxynucleotide (ODN) of SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ
ID NO:
11, SEQ ID NO: 12, SEQ ID NO: 13, or a combination thereof

[0036] In some embodiments, a 0.5 ml dose of the immunogenic composition comprises from about 750 to about 3000 pg of the oligonucleotide, or wherein the immunogenic composition comprises about 750 pig, about 1500 pig, or about 3000 pg of the oligonucleotide.

[0037] The present invention also relates to a method for eliciting an immune response against a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a subject in need thereof, comprising administering to the subject an effective amount of the immunogenic composition of the present invention.

[0038] The present invention also relates to a method for protecting a subject in need thereof from infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), comprising administering to the subject an effective amount of the immunogenic composition of the present invention.

[0039] The present invention also relates to a method for preventing a subject in need thereof from contracting COVID-19 disease, comprising administering to the subject an effective amount of the immunogenic composition of the present invention.

SUBSTITUTE SHEET (RULE 26)

[0040] The present invention also relates to use of the immunogenic composition of the present invention for eliciting an immune response against a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a subject in need thereof, the method comprising administering to the subject in need thereof an effective amount of the immunogenic composition.

[0041] In some embodiments, the immune response comprises production of neutralizing antibodies against SARS-CoV-2 and Thl -skewed immune response.

[0042] The present invention also relates to use of the immunogenic composition of the present invention for protecting a subject in need thereof from infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the method comprising administering to the subject in need thereof an effective amount of the immunogenic composition.

[0043] The present invention also relates to use of the immunogenic composition of the present invention for preventing a subject in need thereof from contracting COVID-19 disease, the method comprising administering to the subject in need thereof an effective amount of the immunogenic composition.

[0044] In some embodiments, the immunogenic composition is administered by intramuscular injection.

[0045] The meaning of the technical and scientific terms as described herein can be clearly understood by a person of ordinary skill in the art.

[0046] As used herein, the singular form "a", "an", and "the" includes plural references unless indicated otherwise. For example, "an" excipient includes one or more excipients.

[0047] The phrase "comprising" as used herein is open-ended, indicating that such embodiments may include additional elements. In contrast, the phrase "consisting of' is closed, indicating that such embodiments do not include additional elements (except for trace impurities).
The phrase "consisting essentially of' is partially closed, indicating that such embodiments may further comprise elements that do not materially change the basic characteristics of such embodiments.

[0048] As used interchangeably herein, the terms "polynucleotide" and "oligonucleotide"
include single-stranded DNA (ssDNA), double-stranded DNA (dsDNA), single-stranded RNA
(ssRNA) and double-stranded RNA (dsRNA), modified oligonucleotides and oligonucleosides or SUBSTITUTE SHEET (RULE 26) combinations thereof The oligonucleotide can be linearly or circularly configured, or the oligonucleotide can contain both linear and circular segments.
Oligonucleotides are polymers of nucleosides joined, generally, through phosphodiester linkages, although alternate linkages, such as phosphorothioate esters may also be used in oligonucleotides. A nucleoside consists of a purine (adenine (A) or guanine (G) or derivative thereof) or pyrimidine (thymine (T), cytosine (C) or uracil (U), or derivative thereof) base bonded to a sugar. The four nucleoside units (or bases) in DNA are called deoxyadenosine, deoxyguanosine, thymidine, and deoxycytidine. A
nucleotide is a phosphate ester of a nucleoside.

[0049] As used herein, the terms "severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)" refers to the strain of coronavirus that causes coronavirus disease 2019 (COVID-19). SARS-CoV-2 is a positive-sense single-stranded RNA virus, with a genome size of 29,903 bases. Each SARS-CoV-2 virion is 50-200 nanometres in diameter, with four structural proteins, known as the S (spike), E (envelope), M (membrane), and N
(nucleocapsid) proteins.
The N protein holds the RNA genome, and the S, E, and M proteins together create the viral envelope. The spike protein is the protein responsible for allowing the virus to attach to and fuse with the membrane of a host cell; specifically, its Si subunit catalyzes attachment, the S2 subunit fusion.

[0050] As used herein, the terms "immunogenic composition against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)" refers to a composition for stimulating or eliciting an immune response against a SARS-CoV-2. The immune response includes, but not limited to, production of neutralizing antibodies against SARS-CoV-2 and Thl -skewed immune response.

[0051] As used herein, the terms "aluminum-containing adjuvant" refers to an adjuvant including aluminum. In some embodiments, the aluminum-containing adjuvant includes, but not limited to, aluminum hydroxide, aluminum oxyhydroxide, aluminum hydroxide gel, aluminum phosphate, aluminum phosphate gel, aluminum hydroxyphosphate, aluminum hydroxyphosphate sulfate, amorphous aluminum hydroxyphosphate sulfate, potassium aluminum sulfate, aluminum monostearate or a combination thereof. In some embodiments, the aluminum-containing adjuvant is an aluminum-containing adjuvant approved for administration to humans by the FDA. In some embodiments, the aluminum-containing adjuvant is an aluminum hydroxide adjuvant approved for administration to humans by the FDA. In some embodiments, the aluminum-containing adjuvant is an aluminum phosphate adjuvant approved for administration to humans by the FDA.

SUBSTITUTE SHEET (RULE 26)

[0052] As used herein, the terms "unmethylated cytosine-phosphate-guanosine (CpG) motif"
refers to a CpG- containing oligonucleotide in which the C is unmethylated, and which contributes to a measurable immune response as measured in vitro, in vivo, and/or ex vivo. In some embodiments, the CpG-containing oligonucleotide contains palindromic hexamers following the general formula of: 5'-purine-purine- CG-pyrimidine-pyrimidine-3'. In some preferred embodiments, the unmethylated cytosine-phosphate-guanosine (CpG) motif has an oligonucleotide of SEQ ID NO: 8 (5'-TGACTGTGAACGTTCGAGATGA-3') in which the Cs of the CGs are unmethylated. In some embodiments, the CpG-containing oligonucleotide contains TCG in which the C is unmethylated, and which is from 8 to 100 nucleotides, preferably 8 to 50 nucleotides, or preferably 8 to 25 nucleotides in length. In some preferred embodiments, the unmethylated cytosine-phosphate-guanosine (CpG) motif has an oligonucleotide of SEQ ID
NO: 9 (5'-TCGTCGTTTTGTCGTTTTGTCGTT-3') in which the Cs of the TCGs are unmethylated. Examples of the unmethylated cytosine-phosphate-guanosine (CpG) motif further includes, but not limited to, 5'-GGTGCATCGATGCAGGGG GG-3' (SEQ ID NO: 10), 5' -TCCATGGACGTTCCTGAGCGTT-3' (SEQ ID NO:
11), 5'-TCGTCGTTCGAACGACGTTGAT-3' (SEQ ID NO: 12), and 5'-TCGTCGACGATCGGC
GCGCGCCG-3' (SEQ ID NO: 13). The CpG-containing oligonucleotide described herein are in their pharmaceutically acceptable salt form unless otherwise indicated. In one preferred embodiment, the CpG-containing oligonucleotides are in the sodium salt form.

[0053] An "effective amount" or a "sufficient amount" of a substance is that amount sufficient to effect beneficial or desired results, including clinical results, and, as such, an "effective amount"
depends upon the context in which it is being applied. In the context of administering an immunogenic composition, an effective amount contains sufficient adjuvant and SARS-CoV-2 5-2P recombinant protein to elicit an immune response. An effective amount can be administered in one or more doses.

[0054] The terms "individual" and "subject" refer to mammals. "Mammals"
include, but are not limited to, humans, non-human primates (e.g., monkeys), farm animals, sport animals, rodents (e.g., mice and rats) and pets (e.g., dogs and cats).

[0055] The term "dose" as used herein in reference to an immunogenic composition refers to a measured portion of the immunogenic composition taken by (administered to or received by) a subject at any one time.
SUBSTITUTE SHEET (RULE 26)

[0056] The terms "isolated" and "purified" as used herein refers to a material that is removed from at least one component with which it is naturally associated (e.g., removed from its original environment). The term "isolated," when used in reference to a recombinant protein, refers to a protein that has been removed from the culture medium of the host cell that produced the protein.

[0057] "Stimulation" of a response or parameter includes eliciting and/or enhancing that response or parameter when compared to otherwise same conditions except for a parameter of interest, or alternatively, as compared to another condition (e.g., increase in TLR-signaling in the presence of a TLR agonist as compared to the absence of the TLR agonist). For example, "stimulation" of an immune response means an increase in the response.
Depending upon the parameter measured, the increase may be from 5-fold to 500-fold or over, or from 5, 10, 50, or 100-fold to 500, 1,000, 5,000, or 10,000-fold.

[0058] As used herein the term "immunization" refers to a process that increases a mammalian subject's reaction to antigen and therefore improves its ability to resist or overcome infection.

[0059] The term "vaccination" as used herein refers to the introduction of vaccine into a body of a mammalian subject.

[0060] "Adjuvant" refers to a substance which, when added to a composition comprising an antigen, nonspecifically enhances or potentiates an immune response to the antigen in the recipient upon exposure.

[0061] The present invention is further illustrated by the following examples, which are provided for the purpose of demonstration rather than limitation. Those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.

[0062] EXAMPLES

[0063] Example 1 Preparation of Immunogenic Compositions Against SARS-CoV-2

[0064] A plasmid having a polynucleotide encoding the residues 1-1208 of SARS-CoV-2 S
protein (Wuhan-Hu-1 strain; GenBank: MN908947) with proline substitutions at residues 986 and 987, a "GSAS" substitution at the furin cleavage site (residues 682 - 685) (SEQ ID NO: 14) and a C-terminal T4 fibritin trimerization domain (SEQ ID NO: 2), an FIRV3C
protease cleavage SUBSTITUTE SHEET (RULE 26) site (SEQ ID NO: 3), an 8x His Tag, and a Twin-Strep Tag (SEQ ID NO: 4) was transfected into ExpiCHO-S cells (Thermo Fisher Scientific, Waltham, MA, USA).

[0065] Cell culture was harvested after 6 days, and protein was purified from the supernatant using Strep-Tactin resin (IBA Lifesciences, Gottingen, Germany). HRV3C
protease (1% wt/wt) was added to the protein and the reaction was incubated overnight at 4 C. The digested protein was further purified using a Superose 6 16/70 column (GE Healthcare Biosciences, Chicago, IL, USA). The purified SARS-CoV-2 S-2P recombinant protein (SEQ ID NO: 5 or 6) was then formulated with an unmethylated CpG motif (CpG 1018, SEQ ID NO: 8) and/or aluminum-containing adjuvant, such as aluminum hydroxide (Al(OH)3) or aluminum phosphate (A1PO4) as the immunogenic compositions against SARS-CoV-2.

[0066] Example 2 Immunogenicity of the Immunogenic Compositions Against SARS-CoV-2 in Mice

[0067] This example provides a description of preclinical studies to assess the immunogenicity of the immunogenic compositions against SARS-CoV-2 obtained from Example 1 in mice.

[0068] A. Preliminary test 1- SARS-CoV-2 S-2P recombinant protein formulated with aluminum phosphate

[0069] Materials and Methods

[0070] Mouse immunizations. BALB/c mice aged 6-8 weeks (The Laboratory Animal Center, Taiwan) (N = 5/group) were vaccinated with the SARS-CoV-2 S-2P recombinant protein at 0 and 3rd week. SARS-CoV-2 S-2P recombinant protein (a final concentration of 1 lig or 10 pg/mL) diluted in PBS was mixed with aluminum phosphate (to a final concentration of 0.5 mg aluminum/mL). Mice were inoculated with 100 p,L intramuscularly (50 pL into each hind leg).
Two weeks after the final immunization, sera were collected for measurement of antibody responses.

[0071] Pseudovirus production. cDNA encoding spike protein of Wuhan-Hu-1 strain (SEQ ID
NO: 7) was synthesized using the QuikChange XL kit (Stratagene, San Diego, CA, USA) and then inserted into CMV/R plasmid. The CMV/R-SARS-CoV-2 spike plasmid was confirmed using sequencing. HEK293T cells were obtained from ATCC and cultured in DMEM
supplemented with 10% FBS, 2 mM glutamine, and 1% penicillin/streptomycin at 37 C and 5%

SUBSTITUTE SHEET (RULE 26) CO2. To produce SARS-CoV-2 pseudoviruses, CMV/R-SARS-CoV-2 spike plasmid was co-transfected into HEK293T cells with packaging plasmid pCMVDR8.2 and transducing plasmid pHR CMV-Luc, using Fugene 6 transfection reagent (Promega, Madison, WI, USA).
Seventy-two (72) hours post-transfection, supernatant was collected, filtered, and frozen at -80 C.

[0072] Pseudovirus infectivity and neutralization assay Huh7.5 cells (RRID:
CVCL7927) were cultured in DMEM supplemented with 10% FBS, 2 mM glutamine, and 1%
penicillin/streptomycin at 37 C and 5% CO2. Pseudovirus infectivity was assessed in Huh7.5 cells plated overnight in 96-well black/white isoplates (PerkinElmer, Waltham, MA, USA).
Twofold serial dilutions of pseudoviruses were added to resting Huh7.5 cells, in triplicate. After a 2-hour incubation, fresh medium was added. Cells were lysed at 72 hours, and luciferase substrate (Promega) was added. Luciferase activity was measured as relative luciferase units (RLU) at 570 nm on a SpectramaxL (Molecular Devices, San Jose, CA, USA). For neutralization experiments, serial dilutions of mouse sera (1:40, fourfold, eight dilutions) were mixed with various pseudovirus strains, which were previously titered to target 50,000 RLU. Sigmoidal curves, taking averages of triplicates at each dilution, were generated from RLU readings; 50%
neutralization titers (IC50) were calculated considering uninfected cells as 100% neutralization and cells transduced with only virus as 0% neutralization.

[0073] Results

[0074] The results of neutralization assay are shown in FIG. 1. SARS-CoV-2 S-recombinant protein (0.1 g/mouse and 1 g/mouse) formulated with aluminum phosphate elicited greater neutralization than the recombinant protein (0.1 g/mouse and 1 g/mouse) alone.
These data demonstrate that aluminum phosphate significantly increase the immunogenicity of the SARS-CoV-2 S-2P recombinant protein as an antigen of a vaccine against coronavirus disease (COVID-19).

[0075] B. Preliminary test 2- SARS-CoV-2 S-2P recombinant protein formulated with the combination of CpG and aluminum hydroxide

[0076] Materials and Methods

[0077] Mouse immunizations. BALB/c mice aged 6-8 weeks (The Laboratory Animal Center, Taiwan) (N = 6/group) were vaccinated with the SARS-CoV-2 S-2P recombinant protein at 0 and SUBSTITUTE SHEET (RULE 26) 3rd week. SARS-CoV-2 S-2P recombinant protein (a final concentration of 10 p.g or 50 pg/mL) diluted in PBS was mixed with CpG 1018 (SEQ ID NO: 8) (to a final concentration of 0.1 mg/mL), aluminum hydroxide (to a final concentration of 0.5 mg aluminum/mL), or a combination of CpG 1018 (to a final concentration of 0.1 mg/mL) and aluminum hydroxide (to a final concentration of 0.5 mg aluminum/mL), respectively. Mice were inoculated with 100 pL
intramuscularly (50 pL into each hind leg). Two weeks after the final immunization, sera were collected for measurement of antibody responses.

[0078] Pseudovirus production, pseudovirus infectivity, and neutralization assay. The methods are described in section A.

[0079] Results

[0080] The results of neutralization test are shown in FIG 2. SARS-CoV-2 S-2P
recombinant protein formulated with the combination of CpG and aluminum hydroxide elicited the highest neutralizing activity both at a low dose (1 g/mouse) and a higher dose (5 g/mouse). In addition, SARS-CoV-2 S-2P recombinant protein (1 g/mouse) formulated with aluminum hydroxide alone elicited greater neutralization than the recombinant protein (1 g/mouse and 5 g/mouse) formulated with CpG alone. The recombinant protein formulated with CpG alone elicited neutralizing activity in a dose-dependent manner. These data demonstrate that CpG and/or aluminum hydroxide significantly increase the immunogenicity of the SARS-CoV-2 recombinant protein as an antigen of a vaccine against coronavirus disease (COVID-19).

[0081] C. Development of adjuvanted stable prefusion SARS-CoV-2 spike protein antigen

[0082] Materials and Methods

[0083] Pseudovirus production and titration. To produce SARS-CoV-2 pseudoviruses, a plasmid expressing full-length wild-type Wuhan-Hu-1 strain SARS-CoV-2 spike protein (SEQ
ID NO: 7) was co-transfected into HEK293T cells with packaging and reporter plasmids pCMVA8.91 and pLAS2w.FLuc.Ppuro (RNAi Core, Academia Sinica), using TransIT-transfection reagent (Mirus Bio). Site-directed mutagenesis was used to generate the D614G
variant by changing nucleotide at position 23403 (Wuhan-Hu-1 reference strain) from A to G.
Mock pseudoviruses were produced by omitting the p2019-nCoV spike (WT).
Seventy-two hours post-transfection, supernatants were collected, filtered, and frozen at ¨80 C. The transduction SUBSTITUTE SHEET (RULE 26) unit (TU) of SARS- CoV-2 pseudotyped lentivirus was estimated by using cell viability assay in response to the limited dilution of lentivirus. In brief, HEK-293 T cells stably expressing human ACE2 gene were plated on 96-well plate 1 day before lentivirus transduction.
For the titering of pseudovirus, different amounts of pseudovirus were added into the culture medium containing polybrene. Spin infection was carried out at 1100xg in 96-well plate for 30 min at 37 C. After incubating cells at 37 C for 16 hours, the culture media containing virus and polybrene were removed and replaced with fresh complete DMEM containing 2.5 [ig/m1 puromycin.
After treating with puromycin for 48 h, the culture media were removed and cell viability was detected by using 10% AlarmaBlue reagents according to manufacturer's instruction. The survival rate of uninfected cells (without puromycin treatment) was set as 100%. The virus titer (transduction units) was determined by plotting the survival cells versus diluted viral dose.

[0084] Pseudovirus-based neutralization assay. HEK293-hAce2 cells (2 x 104 cells/well) were seeded in 96-well white isoplates and incubated for overnight. Sera were heated at 56 C for 30 min to inactivate complement and diluted in MEM supplemented with 2% FBS at an initial dilution factor of 20, and then twofold serial dilutions were carried out (for a total of 8 dilution steps to a final dilution of 1:5120). The diluted sera were mixed with an equal volume of pseudovirus (1000 TU) and incubated at 37 C for 1 h before adding to the plates with cells.
After the 1 h incubation, the culture medium was replaced with 50 !IL of fresh medium. On the following day, the culture medium was replaced with 100 pt of fresh medium.
Cells were lysed at 72 h post infections and relative luciferase units (RLU) were measured. The luciferase activity was detected by Tecan i-control (Infinite 500). The 50% and 90% inhibition dilution titers (ID50 and ID90) were calculated considering uninfected cells as 100% neutralization and cells transduced with only virus as 0% neutralization. Reciprocal ID50 and ID90 geometric mean titers (GMT) were both determined as ID90 titers are useful when ID50 titer levels are consistently saturating at the upper limit of detection.

[0085] Wild-type SARS-CoV-2 neutralization. The neutralization assay with SARS-CoV-2 virus was conducted as previously reported (Huang et al., J. Clin. Microbiol.
58(8): e01068-e1120, 2020). Vero E6 cells (2.5 x 104 cells/well) were seeded in 96-well plates and incubated overnight. Sera were heated at 56 C for 30 min to inactivate complement and diluted in serum-free MEM at an initial dilution factor of 20, and then further twofold serial dilutions were performed for a total of 11 dilution steps to a final dilution of 1:40,960.
The diluted sera were SUBSTITUTE SHEET (RULE 26) mixed with an equal volume of SARS-CoV-2 virus at 100 TCID50/50 [LL (hCoV-19/Taiwan/CGMH-CGU-01/2020, GenBank accession MT192759) and incubated at 37 C
for 2 h. The sera-virus mixture was then added to 96-well plate with Vero E6 cells and incubated in MEM with 2% FBS at 37 C for 5 days. After incubation, cells were fixed by adding 4% formalin to each of the wells for 10 min and stained with 0.1% crystal violet for visualization. Results were calculated with the Reed-Muench method for log 50% end point for ID50 and log 90% end point for ID90 titers.

[0086] Immunization of mice. Female BALB/c and C57BL/6 mice were obtained from the Laboratory Animal Center, Academia Sinica, Taiwan and BioLASCO Taiwan Co. Ltd.
For antigen formulation, SARS-CoV-2 S-2P protein was mixed with either an equal volume of CpG
1018 (SEQ ID NO: 8), aluminum hydroxide, PBS, or CpG 1018 plus aluminum hydroxide. Mice aged 6-9 weeks were immunized twice (50 1_, intramuscularly in each of the left and right quadriceps femoris muscles per mouse) at 3 weeks apart as previously described (Pallesen et al., Proc. Natl. Acad. Sci. USA, 114(35): E7348¨E7357, 2017). Total serum anti-S
IgG and anti-RBD IgG titers were detected with direct ELISA using custom 96-well plates coated with S-2P antigen and an E. co/i-expressed fragment of the S protein containing RBD
region, respectively.

[0087] Cytokine assays. Two weeks after the second injection, mice were euthanized and splenocytes were isolated and stimulated with S-2P protein (2 lag/well) as previously described (Lu et al. Immunology, 130(2): 254-261, 2010). For detection of IFN-y, IL-2, IL-4, and IL-5, the culture supernatant from the 96-well microplates was harvested to analyze the levels of cytokines by ELISA using Mouse IFN-y Quantikine ELISA Kit, Mouse IL-2 Quantikine ELISA
Kit, Mouse IL-4 Quantikine ELISA Kit, and Mouse IL-5 Quantikine ELISA Kit (R&D System).
The OD450 values were read by Multiskan GO (Thermo Fisher Scientific).

[0088] Dose range finding study for single- and repeat-dose intramuscular injection (IM) in Sprague Dawley (SD) rats. Crl:CD Sprague Dawley (SD) rats were obtained from BioLASCO
Taiwan Co. Ltd. Animal studies were conducted in the Testing Facility for Biological Safety, TFBS Bioscience Inc., Taiwan. SD rats aged 6-8 weeks were immunized with 5 lig, 25 lag or 50 lig of S-2P adjuvanted with either 1500 lig CpG 1018 alone or 750 tg CpG 1018 combined with 375 lig aluminum hydroxide. The test article or vehicle control was administered intramuscularly (0.25 mL/site, 2 sites of quadriceps femoris muscle) to each rat on Day 1 (for single-dose study) SUBSTITUTE SHEET (RULE 26) and Day 15 (for repeat-dose study). The observation period was 14 days (for single-dose study) and 28 days (for repeat-dose study). Parameters evaluated included clinical signs, local irritation examination, moribundity/mortality, body temperature, body weights, and food consumption during the in-life period. Blood samples were taken for hematology, including coagulation tests and serum chemistry. All animals were euthanized and necropsied for gross lesion examination, organ weights, and histopathology evaluation on injection sites and lungs.

[0089] Statistical analysis. For neutralization assays, geometric mean titers are represented by the heights of bars with 95% confidence intervals represented by the error bars. For cytokine and rat data, heights of bars or symbols represent means with SD represented by error bars. Dotted lines represent lower and upper limits of detection. Analysis package in Prism 6.01 (GraphPad) was used for statistical analysis. The data were compared at the same S-2P
dose level with different adjuvant or at the same adjuvant system with varying antigen dose.
Kruskal¨Wallis with corrected Dunn's multiple comparisons test was used for non-parametric test between more than 2 experimental groups. Mann¨Whitney U-test was used to compare two experimental groups. For correlation between antibody titers and neutralization titers, Spearman's rank correlation coefficient was used. *p <0.05, **p < 0.01, ***p < 0.001.

[0090] Results

[0091] Induction of potent neutralizing antibodies by CpG 1018 and aluminum hydroxide-adjuvanted S-2P. To facilitate establishment of stable clones for clinical studies and commercial production, the ExpiCHO system was used as the expression system of S-2P antigen.
The S-2P proteins produced in CHO cells and their structure displayed typical spike trimers under cryo-EM, resembling that of 293-expressed SARS-CoV-2 S protein (Wrapp et al., Science, 367(6483): 1260-1263, 2020), suggesting that CHO cells are feasible in production of S-2P. Next, the potential of Thl -biasing CpG 1018 for clinical use was examined. Aluminum hydroxide (hereafter abbreviated as alum) was tested along with CpG 1018 since alum has been characterized to enhance the potency of CpG adjuvant when used in combination while also retaining the property of inducing Thl responses (Thomas et al., Hum. Vaccin., 5(2): 79-84, 2009). The pseudovirus neutralization assay was performed with sera drawn either 3 weeks after the first injection or 2 weeks after the second injection. At 3 weeks after the first injection, neutralizing activities were already observed when mice were immunized with both 1 and 5 lag of S-2P with CpG 1018 and alum. At 2 weeks after the second injection, reciprocal inhibition SUBSTITUTE SHEET (RULE 26) dilution 50 (ID50) GMT of 245, 3109, and 5120 were obtained with immunization of 1 lag S-2P
adjuvanted with CpG 1018, alum, and with both CpG 1018 and alum, respectively (FIG. 3).
Similar trends were observed at 5 lig of S-2P in both BALB/c (FIG. 3) and C57BL/6 mice.

[0092] Sera from these mice were then examined for the amount of anti-S IgG.
CpG 1018 in combination with alum produced significantly higher titers of anti-S IgG
compared to CpG 1018 alone (FIG. 4). To confirm the activities of the antibodies against the critical receptor-binding domain (RBD) of the S protein, immune sera were examined for anti-RBD IgG and the results were similar to that of the anti-S IgG with S-2P in combination with both CpG
1018 and alum induced the highest amount of IgG titer. There was a moderate correlation between anti-S IgG
and anti-RBD IgG titers as shown by Spearman's rank correlation coefficient of 0.6486. The immune sera were further tested for their neutralization capabilities against wild-type SARS-CoV-2 in a neutralization assay. S-2P was able to inhibit SARS-CoV-2 at a concentration of 1 lig, although at lower potency than that of pseudovirus (FIG. 3, FIG. 5). The reciprocal ID50 GMT of 1 tg S-2P in the presence of CpG 1018, alum, and with both CpG 1018 and alum were approximately 60, 250, and 1500, respectively (FIG. 5). Pseudovirus carrying the current dominant D614G variant spike was also generated and neutralizing antibodies from mice immunized with S-2P with CpG 1018 and alum were effective against both pseudoviruses carrying the wild-type D614 and mutant D614G versions of spike proteins (FIG.
6).
Neutralization titers of wild-type virus and pseudovirus and total anti-S IgG
titers were all found to be highly correlated with Spearman's rank correlation coefficients greater than 0.8.

[0093] CpG 1018 induced Th 1 immunity. To identify whether CpG 1018 could induce Thl responses in the vaccine-adjuvant system, cytokines involved in Thl and Th2 responses were measured in splenocytes from mice immunized with S-2P with alum, CpG 1018, or combination of the two. As expected, S-2P adjuvanted with alum induced limited amounts of IFN-y and IL-2, the representative cytokines of Thl response. In contrast, significant increases in IFN-y and IL-2 were detected most strongly in high antigen dose plus CpG 1018 and alum. For Th2 response, while the levels of IL-4, IL-5 and IL-6 increased in the presence of alum and S-2P, addition of CpG 1018 to alum suppressed the levels of IL-5 and IL-6. IFN-y/IL-4, IFN-y/IL-5, and IFN-y/IL-6 ratios are strongly indicative of a Thl -biased response and were increased by approximately 36-, 130-, and two-fold, respectively, in the presence of S-2P combined with CpG 1018 and alum (FIG. 7). These results suggested that the effect of CpG 1018 is dominant over alum in directing SUBSTITUTE SHEET (RULE 26) the cell-mediated response towards Thl response, while retaining high antibody levels.

[0094] S-2P did not result in systemic adverse effects in rats. To elucidate the safety and potential toxicity of the vaccine candidate, 5 ug, 25 ug or 50 g of S-2P
adjuvanted with 1500 ug CpG 1018 or 750 tg CpG 1018 combined with 375 ug alum were administered to SD
rats for single-dose and repeat-dose studies. No mortality, abnormality of clinical signs, differences in body weight changes, body temperature, nor food consumption were observed in either gender that could be attributed to S-2P (with or without adjuvant) with single dose administration.
Increased body temperature at 4-h or 24-h after dosing was found in both genders of single-dose study and repeat-dose study; however, these temperature changes were moderate and were recovered after 48-h in both genders of all treated groups including controls (PBS). No gross lesions were observed in organs of most of the male and female rats with single-dose and two-dose administration, except for one male rat which was deemed to be non-vaccine-related. In conclusion, S-2P protein, with CpG 1018 or CpG 1018 with alum as adjuvants administrated intramuscularly once or twice to SD rats did not induce any systemic adverse effect.

[0095] The results show that in mice, two injections of a subunit vaccine consisting of the prefusion spike protein (S-2P) adjuvanted with CpG 1018 and alum were effective in inducing potent neutralization activity against both pseudovirus expressing wild-type and D614G variant spike proteins, and wild-type SARS-CoV-2. The combination of S-2P with CpG
1018 and alum elicited Thl -dominant immune responses with high neutralizing antibody levels in mice and showed no major adverse effects in rats. Therefore, the inventors have demonstrated in this Example that the S-2P combined with adjuvant CpG 1018 in combination with alum induced potent Thl -biased immune responses to prevent wild-type virus infections while retaining high antibody levels that show cross-neutralization of variant viruses. Therefore, the immunogenic compositions against SARS-CoV-2 of the present invention serves as an ideal vaccine candidate in alleviating the burden of the global COVID-19 pandemic.

[0096] Example 3 Protection from SARS-CoV-2 Challenge by the Immunogenic Compositions Against SARS-CoV-2 in Hamster

[0097] Materials and Methods

[0098] Pseudovirus-based neutralization assay and IgG ELISA. Lentivirus expressing the Wuhan-Hu-1 strain SARS-CoV-2 spike protein was constructed and the neutralization assay SUBSTITUTE SHEET (RULE 26) performed as described in Example 2. Briefly, HEK293-hACE2 cells were seeded in 96-well white isoplates and incubated overnight. Sera from vaccinated and unvaccinated hamsters were heat-inactivated and diluted in MEM supplemented with 2% FBS at an initial dilution factor of 20, and then 2-fold serial dilutions were carried out for a total of 8 dilution steps to a final dilution of 1:5120. The diluted sera were mixed with an equal volume of pseudovirus (1,000 TU) and incubated at 37 C for 1 hour before adding to the plates with cells. Cells were lysed at 72 hours post-infection and relative luciferase units (RLU) was measured. The 50%
and 90%
inhibition dilution titers (ID50 and ID90) were calculated referencing uninfected cells as 100%
neutralization and cells transduced with only virus as 0% neutralization.
Total serum anti-S IgG
titers were detected with direct ELISA using custom 96-well plates coated with S-2P antigen.

[0099] Immunization and challenge of hamsters. Female golden Syrian hamsters aged 6-9 weeks old on study initiation were obtained from the Laboratory Animal Center (Taipei, Taiwan).
The hamsters were randomized from different litters into four groups (n=10 for each group):
hamsters were vaccinated intramuscularly with 2 injections of vehicle control (PBS), 1 or 5 pg of S-2P protein adjuvanted with 150 ig CpG 1018 and 75 lig aluminum hydroxide (alum), or adjuvant alone at 3 weeks apart. The hamsters were bled at 2 weeks after the second immunization via submandibular vein to confirm presence of neutralizing antibodies. Hamsters were challenged at 4 weeks after the second immunization with 1 x 104 PFU of SARS- CoV-2 TCDCitil (hCoV-19/Taiwan/4/2020, GISAID Accession TD: EPI _ ISL _411927) intranasally in a volume of 100 0_, per hamster. The hamsters were divided into two cohorts to be euthanized on 3 and 6 days after challenge for necropsy and tissue sampling. Body weight and survival rate for each hamster were recorded daily after infection. On days 3 and 6 after challenge, hamsters were euthanized by carbon dioxide. The right lung was collected for viral load determination (RNA
titer and TCID50 assay). The left lung was fixed in 4% paraformaldehyde for histopathological examination.

[0100] Quantification of viral titer in lung tissue by cell culture infectious assay (TCID50). The middle, inferior, and post-caval lung lobes of hamsters were homogenized in 600 pi of DMEM
with 2% FBS and 1% penicillin/streptomycin using a homogenizer. Tissue homogenate was centrifuged at 15,000 rpm for 5 minutes and the supernatant was collected for live virus titration.
Briefly, 10-fold serial dilutions of each sample were added onto Vero E6 cell monolayer in quadruplicate and incubated for 4 days. Cells were then fixed with 10%
formaldehyde and SUBSTITUTE SHEET (RULE 26) stained with 0.5% crystal violet for 20 minutes. The plates were washed with tap water and scored for infection. The fifty-percent tissue culture infectious dose (TC1D50)/mL was calculated by the Reed and Muench method (Reed and Muench, American Journal of Epidemiology, 27(3):
493-497, 1938).

[0101] Real-time RT-PCR for SARS-CoV-2 RNA quantification. To measure the RNA
levels of SARS-CoV-2, specific primers targeting 26,141 to 26,253 region of the envelope (E) gene of SARS-CoV-2 genome were used in a TaqMan real-time RT-PCR method (Corman et al., Eurosurveillance. 25(3): 2000045, 2020). Forward primer E-Sarbeco-F1 5'-ACAGGTACGTTAATAGTTAATAGCGT-3' (SEQ ID NO: 15) and the reverse primer E-Sarbeco-R2 5'-ATATTGCAGCAGTACGCACACA-3' (SEQ ID NO: 16), in addition to the probe E-Sarbeco-P1 5'-FAM-ACACTAGCCATCCTTACTGCGCTTCG-BBQ-3' (SEQ ID NO:
17) were used. A total of 30 L RNA solution was collected from each lung sample using RNeasy Mini Kit (QIAGEN, Germany) according to the manufacturer's instructions. Five (5) !IL
of RNA sample was added into a total 25 pi, mixture of the Superscript III one-step RT-PCR
system with Platinum Taq Polymerase (Thermo Fisher Scientific, USA). The final reaction mix contained 400 nM forward and reverse primers, 200 nM probe, 1.6 mM of deoxyribonucleoside triphosphate (dNTP), 4 mM magnesium sulfate, 50 nM ROX reference dye, and 1 L
of enzyme mixture. Cycling conditions were performed using a one-step PCR protocol: 55 C
for 10 min for first-strand cDNA synthesis, followed by 3 min at 94 C and 45 amplification cycles at 94 C for 15 sec and 58 C for 30 sec. Data was collected and calculated by Applied Biosystems 7500 Real-Time PCR System (Thermo Fisher Scientific, USA). A synthetic 113-bp oligonucleotide fragment was used as a qPCR standard to estimate copy numbers of the viral genome. The oligonucleotides were synthesized by Genomics BioSci and Tech Co. Ltd.
(Taipei, Taiwan).

[0102] Results

[0103] Hamsters as SARS-CoV-2 virus challenge model. To develop a SARS-CoV-2 virus challenge model in hamsters for the S2-P vaccine, an initial study was conducted to determine the optimal dose of virus for the challenge experiments. Unvaccinated hamsters were inoculated with 103, 104, or 105 PFU of SARS-CoV-2 and euthanized on Day 3 or 6 after infection for tissue sampling. Following infection of 103 to 105 PFU of SARS-CoV-2, the hamsters exhibited dose-dependent weight loss. Hamsters infected with 103 PFU gained weight while

104 and 105 PFU- infected hamsters experienced progressively severe weight loss at 6 days post-infection SUBSTITUTE SHEET (RULE 26) (dpi). However, there were no significant differences between levels of viral genome RNA and viral titer measured in 103 to 105 PFU of SARS-CoV-2-infected hamsters at 3 and 6 dpi. All dosages of virus resulted in elevated lung pathology, even at 103 PFU where the animals did not experience weight loss. There was also no virus inoculation dose-dependent effect on lung pathology scores and lung viral load. Therefore 104 PFU of virus was used for virus challenge studies as it provides an adequate balance between clinical signs and virus titer for inoculation.
[0104] Administration of S-2P adjuvanted with CpG 1018 and aluminum hydroxide to hamsters induced high levels of neutralizing antibodies. Hamsters were divided into four groups receiving two immunizations at 21 days apart of either vehicle control (PBS
only), adjuvant alone, low dose (LD) or high dose (HD) of S-2P in combination with CpG 1018 and aluminum hydroxide (S-2P+CpG 1018+alum). No differences in body weight changes were observed after vaccination among the four groups. Fourteen days after the second immunization, high level of neutralizing antibody titers were found in both LD and HD groups with ninety-percent inhibition dilution (ID90) geometric mean titer (GMT) of 2,226 and 1,783, respectively (FIG. 8A). Anti-S
IgG antibody levels were high enough that several individual samples reached the upper threshold of detection, with GMTs of LD and HD groups of 1,492,959 and 1,198,315, respectively (FIG. 8B). In general, even at a low dose, S-2P+CpG 1018+alum induced potent levels of immunogenicity in hamsters.

[0105] Adjuvanted S-2P protected hamsters from clinical signs and viral load after SAPS-CoV-2 challenge. Four (4) weeks after the second immunization, hamsters were challenged with 104 PFU of SARS-CoV-2 virus and body weights were tracked up to 3 or 6 days post infection (dpi). Groups of animals were sacrificed on 3 or 6 dpi for viral load and histopathology analyses.
LD and HD vaccinated groups did not show weight loss up to 3 or 6 days after virus challenge and instead gained 5 and 3.8 g of mean weight at 6 dpi, respectively. The protective effect was most significant at 6 dpi in both vaccinated groups, while vehicle control and adjuvant only groups experience significant weight loss. Lung viral load measured by viral RNA and TCID50 assays showed that both viral RNA and viral titer decreased significantly at 3 dpi in vaccinated hamsters and dropped to below the lower limit of detection at 6 dpi (FIGS. 9A-9B). Note that viral load, especially viral titer measured by TCID50 dropped noticeably at 6 dpi in control and adjuvant only groups due to hamsters' natural immune response (FIGS. 9A-9B).
Lung sections were analyzed and pathology scoring was tabulated (FIG. 10). There were no differences at 3 dpi SUBSTITUTE SHEET (RULE 26) between control and experimental groups; however, at 6 dpi, the vehicle control and adjuvant only groups had significantly increased lung pathology including extensive immune cell infiltration and diffuse alveolar damage, compared to the RD antigen/adjuvant immunized groups (FIG. 10). These results showed that S-2P+CpG 1018+alum induced a robust immune response that was able to suppress viral load in lungs and prevent weight loss and lung pathology in infected hamsters.

[0106] All of the hamsters in the S-2P+CpG 1018+alum-immunized groups were protected with significantly reduced lung pathology (generally graded minimal to mild, with a mean score of 1.72 in LD and HD groups), in contrast to diffuse alveolar damage (graded moderate to severe, with a mean score of 4.09 in vehicle and adjuvant control groups) caused by the virus in the lungs of hamsters, in the control groups at 6 dpi. The significance of this study lies not only in the demonstration of in vivo efficacy, but also in safety. The viral challenge study allowed for the assessment of risk of disease enhancement with the vaccine candidate. The histopathology scores of the immunized groups have not differed from the non-challenged animals, indicative of a lack of vaccine-enhanced pathology. The result of the study in this Example provides more data that supports progression of the vaccine candidate's clinical development.

[0107] Example 4 Safety and Immunogenicity of a CpG-adjuvanted S-2P Subunit Vaccine "MVC-COV1901" in Humans

[0108] This Example provides a Phase I study conducted in healthy, human subjects to assess safety and immunogenicity of a SARS-CoV-2 subunit vaccine (i.e., the immunogenic composition of the present invention). The SARS-CoV-2 subunit vaccine, which is referred to herein as "S-2P+CpG 1018+alum" or "MVC-COV1901", is described in greater detail in Example 1.

[0109] Vaccines. MVC-COV1901 is formulated in with three different dosages of SARS-CoV-2 Spike (S) protein with CpG 1018 and aluminum hydroxide as adjuvants.
Each MVC-COV1901 vaccine contains 5, 15, or 25 pg of S-2P adjuvanted with 750 pg of CpG 1018 and 375 lig (Al equivalent to weight) of aluminum hydroxide, administered as a single 0.5 mL
intramuscular (IM) injection.

[0110] Participant. The study aimed to enroll 45 subjects. Eligible participants were healthy adults 20 to 49 years of age. Eligibility was determined based on medical history, physical SUBSTITUTE SHEET (RULE 26) examination, laboratory tests, and investigators' clinical judgment. Exclusion criteria included a history of known potential exposure to SARS CoV-1 or 2 viruses, having received any other COVID-19 vaccine, impaired immune function, history of autoimmune disease, uncontrolled HIV, HBV, or HCV infection, abnormal autoantibody tests, febrile or acute illness within 2 days of first dose, and acute respiratory illness within 14 days of first dose.

[0111] Study Design. This study is a phase I prospective, open-labeled, single-center study to evaluate the safety and immunogenicity of the SARS-CoV-2 vaccine MVC-COV1901.
This study was a dose escalation study with three separate groups of participants 20 to 49 years of age.
Each sub-phase consisted of 15 participants. The three different dose levels employed were 5, 15, and 25 ps of S-2P protein for cohort la, 1 b, and 1 c, respectively. The vaccination schedule consisted of two doses, administered by IM injection in the deltoid muscle of the non-dominant arm 28 days apart, on Day 1 and Day 29.

[0112] Cohort la: Four sentinel participants were to be recruited to receive vaccine with 5 lig of S-2P to evaluate the preliminary safety data of the vaccine. If no Grade 3 adverse event (AE) or serious adverse event (SAE) occurred within 7 days after the first dose in the 4 sentinel participants, dosing of the remaining participants in Phase la and Phase lb would proceed.

[0113] Cohort lb: Another 4 sentinel participants were to be enrolled to receive vaccine with 15 lig of S-2P. If no > Grade 3 AE or SAE occurred within 7 days after the first dose in the 4 sentinel participants, dosing of the remaining participants in Phase lb and Phase 1 c would proceed.

[0114] Cohort lc: Another 4 sentinel participants would be enrolled to receive vaccine with 25 lig of S-2P. If no > Grade 3 AE or SAE occurred within 7 days after the first dose in the 4 sentinel participants, dosing of the remaining participants in Phase lc would proceed.

[0115] Vital signs and electrocardiogram (ECG) were performed before and after vaccination.
Participants were observed for at least 30 min after each dose to identify any immediate AEs, and were asked to record solicited local (pain, erythema, swelling/induration) and systemic (fever, myalgia, malaise/fatigue, nausea/vomiting, diarrhea) AEs in the participant's diary card for up to 7 days after each dose. Unsolicited AEs were recorded for 28 days following each dose; all other AEs, SAEs and adverse events of special interest (AESIs) were recorded throughout the study period (approximately 7 months). Serum samples were collected for hematology, biochemistry SUBSTITUTE SHEET (RULE 26) and immunology evaluation.

[0116] The immunogenicity endpoints were to evaluate neutralizing antibody titers and binding antibody titers at 14 days (Day 15) and 28 days (Day 29) after first and at 14 days (Day 43) and 28 days (Day 57) after second dose, as well as 90 days and 180 days after the second dose. Convalescent serum specimens from 35 recovered COVID-19 patients (Mitek Panel 1.1 and COVID-19 Panel 1.4 obtained from Access Biologicals LLC, Vista, CA, USA) were also tested. Cellular immune responses were evaluated at 28 days after the second dose by IFN-y ELISpot and IL-4 ELISpot.

[0117] SARS-CoV-2 Spike-Specific Immunoglobulin G (IgG): Total serum anti-Spike IgG titers were detected with direct enzyme-linked immunosorbent assay (ELISA) using customized 96-well plates coated with S-2P antigen.

[0118] SARS-CoV-2 Pseudovirus Neutralization Assay: Serial dilutions of the samples to be tested were performed (initial dilution of 1:20 followed by two-fold dilutions to a final dilution of 1:2560). The diluted serum was mixed with an equal volume of pseudovirus (1000 TU) and incubated before adding to the plates with HEK293-hAce2 cells (1 x 104 cells/well). The amount of pseudovirus entering the cells was calculated by lysing and measuring the relative luciferase units (RLU). Fifty percent inhibition dilution (concentration) titers (ID50) were calculated considering uninfected cells as 100% neutralization and cells transduced with virus as 0%
neutralization and reciprocal ID50 geometric mean titers (GMT) were both determined.

[0119] Wild-Type SARS-CoV -2 Neutralization Assay.
SARS-CoV-2 virus (hCoV-19/Taiwan/CGMH-CGU-01/2020, GenBank accession MT192759) was titrated to obtain TOD50 and Vero E6 cells (2.5 x 104 cells/well) were seeded in 96-well plates and incubated. The sera underwent two-fold dilutions with the final dilution being 1:8192, and the diluted sera were mixed with equal volume of viral solution containing 100 TCID50. The serum-virus mixture was incubated and then added to the plates containing the Vero E6 cells, followed by further incubation. The neutralizing titer was defined as the reciprocal of the highest dilution capable of inhibiting 50% of cytopathic effect (CPE NT50), which was calculated in using the Reed-Muench method. The National Institute for Biological Standards and Control (NIBSC;
Potters Bar, UK) reference serum sample 20/130, was analyzed using the same validated assays as a comparator.

[0120] Cellular Immune Response. The number of antigen-specific IFN-y or IL-4 secreting SUBSTITUTE SHEET (RULE 26) spot forming units (SFU) were determined by ELISpot assays. Cryopreserved peripheral blood mononuclear cells (PBMC) were rapidly thawed and allowed to rest overnight.
Cells were dispensed at 1 x 105 cells per well for IFN-y ELIS pot assay (Human IFN-y ELISpot Kit, Mabtech, Stockholm, Sweden) or 2 x 105 cells per well for IL-4 ELISpot assay (Human IFN-y ELISpot Kit, Mabtech, Stockholm, Sweden). Cells were stimulated with a pool of peptides consisting mainly of 15-mer sequences with 11 amino acids overlap, covering the N-terminal Si domain of the S
protein of SARS-CoV-2 (PepTivator SARS-CoV-2 Prot SI, Miltenyi Biotec) and incubated at 37 C for 24-48 hours. Cells stimulated with CD3-2 mAb served as the positive control. IFN-y or IL-4 release were detected following the manuals and the spots were counted using the CTL
automatic ELISpot reader. The mean SFU counted in peptide pool stimulation triplicate was calculated and normalized by subtracting the mean of the negative control replicates (control media). Results were expressed as SFU per million PBMC.

[0121] Statistical Analysis. Safety analyses were performed on the total vaccinated group (TVG) population who received at least 1 dose of vaccine. The immunogenicity endpoints comprised the geometric mean titer (GMT) and seroconversion rate (SCR) of antigen specific immunoglobulins and wild type virus and pseudovirus neutralizing antibody titers. SCR is defined as the percentage of participants with > 4-fold increase in titers from the baseline or from half of the lower limit of detection (LoD) if undetectable at baseline. The GMT and SCR are presented with two-sided 95% CI. Antigen specific cellular immune responses are presented as means determined by IFN-y ELISpot and IL-4 ELISpot.

[0122] Results

[0123] Safety. No SAE or AESI occurred at this data cut-off point. No study intervention was modified or interrupted. Occurrences of solicited AEs are summarized in Figure 11. The most commonly reported local AEs were pain/tenderness (80.0%), while malaise/fatigue (28.9%) were the most commonly reported systemic AEs among all treatment groups. All local and systemic AEs were mild, except for one malaise/fatigue in the 25 pg dose group. No participant had fever.
Solicited AEs after the first and the second dose were similar. Evaluation of safety laboratory values, ECG interpretation, and other unsolicited adverse events revealed no specific concern.

[0124] Humoral Immune Response. The humoral immunogenicity results are summarized in FIGS. 12A to 12C. As shown in FIG. 12A, binding IgG titers to S protein increased rapidly after SUBSTITUTE SHEET (RULE 26) the second dose, with seroconversion in all participants by Day 43 and 57. The GMTs peaked at Day 43 with a value of 7178.2 (95% CI: 4240.3 - 12151.7), 7746.1 (95% CI:
5530.2- 10849.8), 11220.6 (95% CI: 8592.293 - 14652.84) in the 5 pig, 15 pig, and 25 lig dose groups, respectively.
The GMT levels in the 5 pig, 15 pig, and 25 ps dose groups on Day 43 ranged from 3.3 to 5.1 times the GMT of convalescent serum specimens. (2179.6, [95%CI: 1240.9 -3828.4]).

[0125] As shown in FIG. 12B, no subject had detectable pseudovirus neutralizing titers (1D5o) at the lower limit of serum concentration tested (1:20 dilution) in the assay at baseline. At Day 43, the pseudovirus neutralizing titers (ID50) showed peak GMTs of 538.5 (95% CI:
261.9- 1107.0), 993.1 (95% CI: 655.0 - 1505.7), and 1905.8 (95% CI: 1601.7 - 2267.8) in the 5 pig, 15 rig, and 25 kg dose groups, respectively. All participants (100%) seroconverted after the second dose. The GMT levels in the 5 pig, 15 rig, and 25 kg dose groups on Day 43 ranged from 1.25 to 4.4 times the GMT of convalescent serum specimens. (430.5, [95%CI: 274.9- 674.0]).

[0126] The results of wild-type SARS-CoV-2 neutralizing antibody titers are summarized in FIG. 12C. Before vaccination, no subject had detectable wild-type virus neutralizing titers (NT50) at the lower limit of serum concentration tested (1:8 dilution) in the assay.
After the second dose, neutralizing responses were identified in serum samples from all participants in the 15 kg and 25 kg dose groups. At Day 43, the GMTs were 33.3 (95% CI: 18.5 - 59.9), 76.3 (95%
CI: 53.7 -108.3), and 167.4(95% CI: 122.1 -229.6) in the 5 fig, 15 ps, and 25 pg dose groups, respectively.
At Day 57, GMTs were similar in the 15 kg and 25 kg dose groups: 52.2 (95% CI:
37.9 - 71.8) and 81.9 (95% CI: 55.8 - 120.2), respectively. The GMT levels in the 5 pig, 15 pig, and 25 ps dose groups on Day 43 were 0.8, 1.8, and 3.9 times the GMT of convalescent serum specimens (42.7, [95%CI: 26.4 - 69.0]; titers ranged from undetected to 631.0). All participants in 15 kg and 25 kg dose groups seroconverted at Day 43 and Day 57; some were similar to the NIBSC
reference serum 20/130 (281.8).

[0127] Cellular Immune Response. The results of cellular immune response are summarized in FIG. 13. All participants had minimal IFN-y secreting T cells at baseline. By Day 57, a mean of 161.3, 85.5 and 94. 9 IFN-y secreting T cells were observed per million cells in participants vaccinated with 5 kg, 15 kg, and 25 pg, respectively. Before vaccination, all participants had minimal IL-4 secreting T cells. By Day 57, a mean of 24.1, 16.0 and 31.3 IL-4 secreting T cells were observed per million cells in participants vaccinated with 5 kg, 15 ps, and 25 ps, respectively. The cellular immune response induced by MVC-COV1901 demonstrated SUBSTITUTE SHEET (RULE 26) substantially higher numbers of IFN-y- producing cells, suggesting a Thl -skewed immune response.

[0128] In conclusion, solicited adverse events were mostly mild and similar. No subject experienced fever. After the second dose, of the three doses evaluated, both the 15 g and 25 lig dose elicited high neutralizing antibody responses with all participants seroconverting and a Thl -skewed T cell immune response. Therefore, 15 ig S-2P combined with CpG
1018 and aluminum hydroxide was deemed adequate to elicit a profound humoral immune response. The results also indicate that MVC-COV1901 vaccine was well tolerated and elicited robust immune responses and is suitable for further development.

[0129] Example 5 Evaluation of the Neutralizing Ability of a CpG-adjuvanted S-Subunit Vaccine "MVC-COV1901" Against SARS-CoV-2 Variants of Concern (VoCs)

[0130] Since the beginning of the COVID-19 pandemic, mutants have been detected periodically. A number of them, termed Variants of Concern (VoCs), were found to carry mutations in the crucial receptor-binding domain (RBD), a prime target for antibody recognition and neutralization. The most representative of these VoC, all bearing an N501Y
mutation in the spike RBD, are B.1.1.1.7 (Alpha variant), B.1.351 (Bata variant), and P1 (Gamma variant). The VoCs with these mutations were found to decrease neutralization capabilities of monoclonal antibodies and vaccine-induced antibodies, and this could potentially render current therapeutics and vaccines ineffective (Garcia-Beltran et al., Cell, 184(9):2372-2383.e9, 2021). This Example provides a study involving investigation of neutralizing ability of MVC-COV1901 vaccine against SARS-CoV-2 VoCs using sera from two sources: rat sera from animal toxicology studies and human sera from phase 1 clinical trial.

[0131] A. Neutralizing ability of MVC-COV1901 vaccine against SARS-CoV-2 VoCs in rats.

[0132] Materials and Methods

[0133] Animal studies. Crl:CD Sprague Dawley (SD) rats were obtained from BioLASCO
Taiwan Co. Ltd. (Taipei, Taiwan), and studies were conducted in the Testing Facility for Biological Safety, TFBS Bioscience Inc. (New Taipei City, Taiwan).
Immunization of SD rats were carried out as described in Example 2, section C. Briefly, rats were immunized three times at two weeks apart with 5, 25, or 50 lig of S-2P protein adjuvanted with 1,500 g of CpG 1018 and 750 lig of aluminum hydroxide. The sera were harvested two weeks after the second SUBSTITUTE SHEET (RULE 26) immunization (Day 29) or two weeks after the third immunization (Day 43) and subjected to neutralization assay with pseudovirus expressing SARS-CoV-2 Wuhan wildtype (WT) or B.1.351 variant (Beta variant) spike proteins.

[0134] Pseudovirus neutralization assay. Lentivirus expressing the SARS-CoV-2 spike proteins of the Wuhan-Hu-1 wildtype strain (WT) was constructed, and the neutralization assay performed as described in Example 2, section C. Lentiviruses expressing B.1.351 variant (Beta variant) spike proteins were constructed in the same manner but with the wild-type spike protein sequence replaced with the variant sequence (GenBank Accession No.
MZ314998.1).

[0135] Statistical analysis. Prism 6.01 (GraphPad Software Inc., San Diego, CA, USA) was used for statistical analysis. Two-way ANOVA with Tukey's multiple comparison test and Kruskal-Wallis with corrected Dunn's multiple comparisons test were used to calculate significance as noted in respective figure descriptions. * p < 0.05, ** p <
0.01, *** p < 0.001, **** p <0.0001.

[0136] Results

[0137] AJVC-COV 190I-induced antibodies in rats effectively neutralized variants comparable to the wildtype. As shown in FIG. 14, at Day 29 and 43, the antibodies retained effectiveness against the B.1.351 (Beta variant), although the titers were reduced. Notably, sera sampled two weeks after the third immunization (Day 43) had higher ID50 and ID90 geometric mean titers (GMT) than sera sampled two weeks after the second immunization (Day 29), suggesting a trend towards improved neutralization activity against this VoC with a third immunization. The effect is especially pronounced in the low (5 ug) dose. By Day 43, all dose groups achieved similar levels of GMTs against B.1.351 at ID50 (FIG. 14, left panel) and ID90 (FIG. 14, right panel).

[0138] To sum up, the rat study shows that by using a three-dose regimen, we were able to induce similar levels of neutralizing titer across three-dose groups. Given that the three-dose regimen resulted in high immunogenicity against the variant, these results could be extrapolated to humans in that an extra immunization could be a strategy to increase immunity against the SUBSTITUTE SHEET (RULE 26) VoCs.

[0139] B. Neutralizing ability of MVC-COV1901 vaccine against SARS-CoV-2 VoCs in human.

[0140] Materials and Methods

[0141] Clinical trial. Forty-five (45) human subjects from the age of 20 to 49 were enrolled in a prospective, open-labeled, single-center dose-escalation phase 1 study with three separate sub-phases for participants from 20 to less 50 years of age. Each sub-phase had 15 participants.
The three different dose levels employed in this clinical trial are low dose (LD; 5 ug), mid-dose (MD; 15 ug) and high dose (HD; 25 ug) of S-2P protein adjuvanted with 750 ug of CpG 1018 and 375 ug of aluminum hydroxide for phase la, lb, and lc, respectively. The vaccination schedule consisted of two doses, administered by intramuscular (IM) injection of 0.5 mL in the deltoid region of the non-dominant arm, preferably 28 days apart, on Day 1 and Day 29. On Day 57 (4 weeks after the second administration), serum samples were taken for pseudovirus neutralization assays. The clinical trial is described in greater detail in Example 4.

[0142] Pseudovirus neutralization assay. Lentivirus expressing the SARS-CoV-2 spike proteins of the Wuhan-Hu-1 wildtype strain (WT) was constructed, and the neutralization assay performed as described in Example 2, section C. Lentiviruses expressing D614G, B.1.1.7 (Alpha variant; GenBank Accession No. MZ314997.1), B.1.351 (Beta variant; GenBank Accession No.
MZ314998.1), P1 (Gamma variant; GenBank Accession No. LR963075), and B.1.429 (Epsilon variant; GenBank Accession No. MW591579) spike proteins were constructed in the same manner but with the wild-type spike protein sequence replaced with the respective variant sequences.

[0143] Statistical analysis. Methods of statistical analysis were performed as described in the previous section.

[0144] Results

[0145] Human antisera from vaccination with MVC-COVI901 neutralized D6I4G, B.I.1.7 (Alpha), PI (Gamma) variants, but neutralization was diminished with B.1.351 (Beta) and B. 1.429 (Epsilon) variants. FIGS. 15A-C present the data from pseudovirus neutralization assays SUBSTITUTE SHEET (RULE 26)

Claims (15)

What is claimed is:

1. An immunogenic composition against a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), comprising an antigenic recombinant protein and an adjuvant selected from the group consisting of an aluminum-containing adjuvant, an unmethylated cytosine-phosphate-guanosine (CpG) motif, and a combination thereof, wherein the antigenic recombinant protein substantially consists of residues 14-1208 of SARS-CoV-2 S protein with proline substitutions at residues 986 and 987 and a "GSAS"
substitution at residues 682 - 685 and a C-terminal T4 fibritin trimerization domain.

2. The immunogenic composition of claim 1, wherein the residues 14-1208 of SARS-CoV-2 S protein with proline substitutions at residues 986 and 987 and a "GSAS"
substitution at residues 682 ¨ 685 comprise an amino acid sequence of SEQ ID
NO: 1 or the amino acid sequence at least 90%, 95%, 96%, 97%, 98%, or 99% to SEQ ID NO:
1.

3. The immunogenic composition of claim 1 or 2, wherein the C-terminal T4 fibritin trimerization motif comprises an amino acid sequence of SEQ ID NO: 2 or the amino acid sequence at least 90%, 95%, 96%, 97%, 98%, or 99% to SEQ ID NO: 2.

4. The immunogenic composition of any one of claims 1-3, wherein the antigenic recombinant protein comprises an amino acid sequence of SEQ ID NO: 5 or 6 or the amino acid sequence at least 90%, 95%, 96%, 97%, 98%, or 99% to SEQ ID NO: 5 or 6.

5. The immunogenic composition of any one of claims 1-4, wherein the aluminum-containing adjuvant comprises aluminum hydroxide, aluminum oxyhydroxide, aluminum hydroxide gel, aluminum phosphate, aluminum phosphate gel, aluminum hydroxyphosphate, aluminum hydroxyphosphate sulfate, amorphous aluminum hydroxyphosphate sulfate, potassium aluminum sulfate, aluminum monostearate or a combination thereof.

6. The immunogenic composition of any one of claims 1-5, wherein a 0.5 ml dose of the immunogenic composition comprises from about 250 to about 500 g A13 , or about 1dg Al3 .

7. The immunogenic composition of any one of claims 1-6, wherein the unmethylated CpG
motif comprises a synthetic oligodeoxynucleotide (ODN) of SEQ ID NO: 8, SEQ ID

NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, or a combination thereof.

8. The immunogenic composition of any one of claims 1-7, wherein a 0.5 ml dose of the immunogenic composition comprises from about 750 to about 3000 pg of the oligonucleotide, or wherein the immunogenic composition comprises about 750 pg, about 1500 pg, or about 3000 pg of the oligonucleotide.

9. A method for eliciting an immune response against a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a subject in need thereof, comprising administering to the subject an effective amount of an immunogenic composition of any one of claims 1-8.

10. The method of claim 9, wherein the immune response comprises production of neutralizing antibodies against SARS-CoV-2 and Thl-skewed immune response.

11. Use of the immunogenic composition of any one of claims 1-8 for eliciting an immune response against a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a subject in need thereof, the method comprising administering to the subject in need thereof an effective amount of the immunogenic composition.

12. The use of claims 11, wherein the immune response comprises production of neutralizing antibodies against SARS-CoV-2 and Thl-skewed immune response.

13. Use of the immunogenic composition of any one of claims 1-8 for protecting a subject in need thereof from infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the method comprising administering to the subject in need thereof an effective amount of the immunogenic composition.

14. Use of the immunogenic composition of any one of claims 1-8 for preventing a subject in need thereof from contracting COVID-19 disease, the method comprising administering to the subject in need thereof an effective amount of the immunogenic composition.

15. The use of any one of claims 11-14, wherein the immunogenic composition is administered by intramuscular injection.